{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-004608","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2021-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.447065+00:00","generated_at":"2026-06-28T08:38:10.871975+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Surrozen Q3 2021 net loss $14.0M; cash $135.4M post business combination","bullets":["Cash, cash equivalents and marketable securities $135.4M as of Sept 30, 2021, up from $18.9M at June 30, 2021.","Net loss of $14.0M for Q3 2021 vs $8.6M in Q3 2020; R&D expenses $10.4M (Q3 2021) vs $7.0M.","Plan to initiate Phase 1a trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) in 2022.","Pre-clinical data for both candidates presented at medical congresses; five new discovery programs initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-004608","json":"https://secwatch.observer/filing/0000950170-21-004608.json","markdown":"https://secwatch.observer/filing/0000950170-21-004608.md","text":"https://secwatch.observer/filing/0000950170-21-004608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000095017021004608/0000950170-21-004608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000095017021004608/srzn-20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T08:38:10.871975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}